Last Update

2016-08-30T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Anthony Rosenberg?

Mr. Anthony Rosenberg

Golbal Head Business Development and Licensing

Novartis AG

Direct Phone: +41 *********       

Email: a***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Novartis AG

Basel,

Switzerland

Company Description

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novart ... more

Find other employees at this company (59,062)

Background Information

Affiliations

Board Member
Radius Health, Inc.

Advisor
Serodus ASA

Board Member
Strategy Committee

Board Member
BioExec Institute

Member of the Executive Committee
Pharma

Advisory Board Member
Technology Vision Group LLC

Head Partnering and Emerging Businesses, Member
Executive Committee Novartis Pharma AG

Head Partnering and Emerging Businesses, Member
Executive Committee Novartis Pharma AG

Board Member
Idenix Pharmaceuticals , Inc.

Head Partnering and Emerging Businesses, Member
Molecular Diagnostics Group

Board Member
Novirio Pharmaceuticals , Inc.

Member
PECS

Education

Bachelor of Science degree

Biological Sciences

University of Leicester

Masters of Science

Physiology

University of London

Web References (164 Total References)


Anthony ...

www.serodus.com [cached]

Anthony Rosenberg

Business development and licensing
Anthony (Tony) Rosenberg served as Global Head M & A / licensing until February 2015 and in that role was responsible for Corporate M & A / Licensing across all Novartis divisions. This included execution of the Novartis Portfolio Transformation, comprising asset swaps/ divestments across several business sectors, which is currently seen as a unique set of transactions in the industry. Prior to this role Mr. Rosenberg was Global Head Business Development and Licensing, Novartis Pharma for 7 years. Earlier in his career in Novartis he was Head of Transplant /Immunology Global Business Unit , after several marketing leadership roles.
Mr. Rosenberg has a B.Sc. (Hons) from University of Leicester, a M.Sc. Physiology from University of London.


Board of Directors - Radius Health

www.radiuspharm.com [cached]

Tony Rosenberg

...
Tony Rosenberg is retired from Novartis where he was Head of M&A and Licensing. Most recently he was responsible for the Portfolio Transformation transactions undertaken by Novartis, which are seen as landmark deals in the industry.
Tony joined Sandoz in 1980 in the UK where he held various leadership positions in sales and marketing, business development and strategic planning. In 1994 he moved to Basle, initially in international product management (Clozaril), and undertook roles of increasing responsibility in Global Marketing, ultimately as Head Global Marketing Primary Care. In 2000 he became Global Head of the Transplant and Immunology Business Unit. In 2005 he was appointed Global Head Business Development & Licensing (Pharma) and has managed major in-licensing transactions in the cardiovascular, CNS, respiratory, infectious disease and oncology areas, as well as divestment and M&A deals. In 2010 he was given additional responsibility for leadership of the Molecular Diagnostics group. In 2013 he was appointed as Head M&A and Licensing (Corporate).
Tony Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.


The current Class I Directors are ...

www.sec.gov [cached]

The current Class I Directors are Owen Hughes, Debasish Roychowdhury, M.D. and Robert E. Ward; the current Class II Directors are Alan H. Auerbach, Catherine J. Friedman, Ansbert K. Gadicke, M.D., and Jean-Pierre Garnier; and the current Class III Directors are Willard H. Dere, M.D., Kurt C. Graves and Anthony Rosenberg.

...
Anthony Rosenberg
...
ANTHONY ROSENBERG
...
Anthony Rosenberg has served on our Board of Directors since March 2015. Mr. Rosenberg has been a Managing Director of MPM Capital, a venture capital firm, since April 2015. From January 2013 to February 2015, Mr. Rosenberg served as Corporate Head of M&A and Licensing at Novartis International, a pharmaceutical company. From March 2005 to December 2012, he served as Global Head of Business Development and Licensing at Novartis Pharmaceuticals. Prior to that, Mr. Rosenberg was Global Head of the Transplant and Immunology Business Unit at Novartis Pharmaceuticals from 2000 to 2005. Mr. Rosenberg initially joined Sandoz, a predecessor to Novartis, in 1980. He currently serves as a director of Clinical Ink and TriNetX. Mr. Rosenberg served as a director of Idenix Pharmaceuticals, Inc. from June 2009 to March 2012 and from December 2012 to March 2013. Mr. Rosenberg holds a B.Sc from the University of Leicester and an M.Sc in physiology from the University of London. We believe Mr. Rosenberg is qualified to serve as a member of our Board of Directors due to his extensive experience in mergers and acquisitions and licensing in the pharmaceutical sector.
...
Our Board of Directors currently consists of ten (10) members: Alan H. Auerbach, Willard H. Dere, M.D., Catherine J. Friedman, Ansbert K. Gadicke, M.D., Jean-Pierre Garnier, Kurt C. Graves, Owen Hughes, Anthony Rosenberg, Debasish Roychowdhury, M.D., and Robert E. Ward.
...
Our Board of Directors has affirmatively determined that each of Alan H. Auerbach, Willard H. Dere, M.D., Catherine J. Friedman, Ansbert K. Gadicke, M.D., Jean-Pierre Garnier, Kurt C. Graves, Owen Hughes, Anthony Rosenberg, and Debasish Roychowdhury, M.D., is an "independent director," as defined under NASDAQ rules.
...
Anthony Rosenberg, a Class III director elected to the Board in 2015, was recommended by a non-management director.


Tony ...

www.radiuspharm.com [cached]

Tony Rosenberg

...
Tony Rosenberg is retired from Novartis where he was Head of M&A and Licensing. Most recently he was responsible for the Portfolio Transformation transactions undertaken by Novartis, which are seen as landmark deals in the industry.
Tony joined Sandoz in 1980 in the UK where he held various leadership positions in sales and marketing, business development and strategic planning. In 1994 he moved to Basle, initially in international product management (Clozaril), and undertook roles of increasing responsibility in Global Marketing, ultimately as Head Global Marketing Primary Care. In 2000 he became Global Head of the Transplant and Immunology Business Unit. In 2005 he was appointed Global Head Business Development & Licensing (Pharma) and has managed major in-licensing transactions in the cardiovascular, CNS, respiratory, infectious disease and oncology areas, as well as divestment and M&A deals. In 2010 he was given additional responsibility for leadership of the Molecular Diagnostics group. In 2013 he was appointed as Head M&A and Licensing (Corporate).
Tony Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.


BIOCOM's 2nd Annual Global Life Science Partnering Conference | Life Science Branding & Marketing Network

www.lsbmn.org [cached]

Tony Rosenberg, Head of Global BD & Licensing, Novartis

Similar Profiles

Other People with this Name

Other people with the name Rosenberg

Paul Rosenberg
The Eye Care Center

Seth Rosenberg
University of Washington School of Law

Ronni Rosenberg
Sheridan College

Mark Rosenberg
National Child Care Association

Eric Rosenberg

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory